juli 28, 2018
SAN DIEGO and COPENHAGEN, Denmark, July 23, 2018 /PRNewswire/ — Dermtreat, a clinical-stage biopharmaceutical company focused on mucosal diseases, today announced treatment of the first patient in a Phase 2b clinical trial of Rivelin® Clobetasol patch (Rivelin®-CLO) for oral lichen planus (OLP). Rivelin-CLO is the first biodegradable oral adhesive patch designed for local delivery of clobetasol...


BONESUPPORT HOLDING AB (publ) announces that the patient enrolment schedule for the ongoing FORTIFY study is extended
21. august 2019
Lundbeckfonden udvider ledelsen med to stærke profiler
8. august 2019
Event: Fra trip til koma – bliv klogere på din bevidsthed
6. august 2019


Lundbeckfonden Ventures

Lundbeckfonden Emerge